RT Book, Section A1 Flurie, Rachel W. A1 Brophy, Donald F. A2 DiPiro, Joseph T. A2 Talbert, Robert L. A2 Yee, Gary C. A2 Matzke, Gary R. A2 Wells, Barbara G. A2 Posey, L. Michael SR Print(0) ID 1153854970 T1 Disorders of Potassium and Magnesium Homeostasis T2 Pharmacotherapy: A Pathophysiologic Approach, 10e YR 2017 FD 2017 PB McGraw-Hill Education PP New York, NY SN 9781259587481 LK accesspharmacy.mhmedical.com/content.aspx?aid=1153854970 RD 2024/03/28 AB Content UpdateMay 24, 2018Sodium Zirconium Cyclosilicate (Lokelma) for Treatment of Hyperkalemia: In May 2018, the U.S. Food and Drug Administration approved sodium zirconium cyclosilicate for treatment of hyperkalemia in adults. The drug is a cation exchange resin that exchanges potassium for sodium and hydrogen in the gut lumen, thereby increasing fecal potassium excretion; this reduces free potassium concentrations and lowers serum potassium levels. It represents the third cation exchange resin available for commercial use in addition to sodium polystyrene sulfonate (Kayexalate) and patiromer sorbitex calcium (Veltassa). Healthcare providers should be knowledgeable about each drug's efficacy, dosing, adverse effects, precautions, drug interactions, and cost prior to clinical use.